Patent provides exclusivity through 2037

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases, announced the issuance of a US patent for its lead product, ST-62516 (trimetazidine). US Patent No. 11,123,345 (’345 patent) provides exclusivity through 2037, with broad claims for the reduction of kidney injury in patients with chronic kidney disease (CKD) undergoing contrast procedures.

"We are very pleased to announce the issuance of the ’345 patent, which will enhance the long-term value of ST-62516,” commented Anna Kazanchyan, M.D., CEO of Saghmos. “This patent lays the foundation for Saghmos’ growing intellectual property estate, including pending international patents as well as additional patent applications that are in preparation.”

Saghmos plans to begin a Phase 3 study of ST-62516 (trimetazidine) for the reduction of cardiorenal complications associated with Contrast-induced Kidney Injury (CIKI) in patients with CKD undergoing contrast procedures. Trimetazidine is a mitochondrial metabolic modulator with clinical evidence of cardiorenal benefits, as well as favorable safety and tolerability shown in numerous published studies.

CIKI is an emerging public health problem, with increased risk of death, heart attacks, heart failure, prolonged hospitalization, and kidney failure leading to need for dialysis. CIKI and associated complications result in billions of dollars in annual healthcare costs, and there are no FDA-approved drugs for this condition.

CIKI has a disproportionate impact on African Americans, with 3.4-fold higher prevalence of End Stage Renal Disease requiring dialysis. “ST-62516 will have broad societal impact by helping achieve health equity,” stated Anna Kazanchyan, M.D.

About Saghmos Therapeutics

Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases with unmet medical need.

Forward looking statements

This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos’ business, intellectual property, clinical and regulatory plans, commercial potential, value and benefits of ST-62516, and its ability to achieve societal impact. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, general changes in the economic environment, and business interruptions resulting from COVID-19 or other systemic events. These forward looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005364/en/

Saghmos Therapeutics, whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases, announced the issuance of a US patent for its lead product, ST-62516. The patent provides exclusivity through 2037.